Trial Profile
A Double Blind Randomised, Comparative Study of the Immunogenicity and Reactogenicity of Three Different Lots of GlaxoSmithKline Biologicals' Combined Hepatitis A - Hepatitis B Vaccine When Administered in Healthy Adults
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Hepatitis A-hepatitis B vaccine (Primary)
- Indications Hepatitis A; Hepatitis B
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 27 Oct 2011 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 02 Feb 2010 Actual end date (Dec 2007) and actual number of patients (50) added as reported by ClinicalTrials.gov.
- 02 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.